- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05184127
Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19
Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.
This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19® via 14 days of treatment of participants with symptomatic moderate COVID-19.
The purpose of this study is to evaluate the efficacy, safety and daily dose of MIR 19 ® for the treatment of the hospitalized patients with infection caused by SARS-CoV-2 (COVID-19) who did not require treatment in the intensive care unit.
Based on preclinical data studying antiviral effect of MIR 19® in vitro and in vivo (Khaitov M.R. et all 2021), the investigators hypothesized that SARS-CoV-2 inhibition with MIR 19® could potentially reduce pulmonary inflammation, thereby improving COVID-19 patient outcomes.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is Phase 2 multi-center controlled randomized study to assess the efficacy and safety of MIR 19 ® in male and female volunteers with symptomatic moderate COVID-19 who did not require treatment in the intensive care unit.
The MIR 19® is a complex of siRNA, targeting SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and peptide dendrimer KK-46.
This study involved 3 cohorts who received:
- standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
- 3.7 mg of the MIR 19 ® via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
- 11.1 mg of the MIR 19 ® via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
All subjects will undergo scheduled safety and efficacy assessments while in the clinical unit and as outpatients to the end of the follow-up period.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Moscow, Federazione Russa, 115478
- NRC Institute of Immunology FMBA
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men or non-pregnant female aged 18 to 65 years hospitalized with moderate COVID-19 infection: body temperature > 37.5 °C; respiratory rate > 22/min; shortness of breath during physical exertion; typical coronavirus-associated chest computed tomography (CT) changes (CT1- CT2); pulse oximetry levels SpO2< 95%.
- Able to give informed consent and attend all study visits
- Positive PCR-test for COVID-19 ≤72 hours prior to randomization
- The patient's ability to inhale the experimental drug
- Participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month
Key Exclusion Criteria:
- Fever > 38.5°C.
- Cough severity is less than 1 point on a 4-point scale.
- Respiratory rate > is more than 30 / min
- SpO2 ≤ 93%.
- Decreased level of consciousness, agitation.
- Unstable hemodynamics (systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg).
- The need to require mechanical ventilation beyond the screening/ randomization.
- Long-term systemic corticosteroid exposure.
- Autoimmune or inflammatory diseases (systemic / localized).
- Positive blood tests for HIV, hepatitis B and С, syphilis.
- Pregnancy and breast-feeding
- Previous adverse reactions to the active substance and/or excipients included in the drug.
- Any use of anti-viral medications or immunomodulatory agents up to 7 days before participating in the study
- Chronic diseases of the cardiovascular system
- Type 1 diabetes
The following laboratory parameters are excluded:
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and direct bilirubin >4 x upper limit of normal (ULN);
- Treatment with any medicine that have a pronounced effects on the blood coagulation system (expect for COVID-19 treatment), including combined oral contraceptives.
- Treatment with any medicine that can affect cardiac conduction
- Participation in other investigational drug or device clinical trials within 90 days prior to screening.
- History of alcohol, drug or chemical abuse.
- Mental illness.
- Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) up to 14 days before participating in the study, vaccination against SARS-CoV-2 , the need for extracorporeal membrane oxygenation.
- Any conditions that, according to the researcher's, may be a contraindication to the participation in the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: MIR 19 ®
Study participants from experimental groups, in addition to standard COVID-19 therapy, received the MIR 19 ® (2 inhalations per day with a single dose of 1.85 or 5.55 mg at intervals of 7-8 hours for 14 days).The standard therapy in this group included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
|
Drug contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use.
Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.
This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
|
Comparatore attivo: Standard COVID-19 therapy
In the comparison group, therapy was carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.The standard therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
|
Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.
This therapy included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.
In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Relief of fever
Lasso di tempo: Within 14 days
|
Reduction in axillary temperature below 37 °C without antipyretic drugs use
|
Within 14 days
|
Respiratory rate
Lasso di tempo: Within 14 days
|
Respiratory rate ≤ 22 per minute
|
Within 14 days
|
Oxygen saturation
Lasso di tempo: Within 14 days
|
SpO2 > 94%
|
Within 14 days
|
Severity of cough
Lasso di tempo: Within 14 days
|
Severity in a patient's cough no more than 1 point on a four-point scale
|
Within 14 days
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SiCoV/KK46- 2021_CSR
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su COVID-19
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNon ancora reclutamentoSindrome post-COVID-19 | Lungo COVID | Lungo Covid19 | Condizione post COVID-19 | Sindrome post-COVID | Condizione post COVID-19, non specificata | Condizione post-COVIDOlanda
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...CompletatoSequele post acute di COVID-19 | Condizione post COVID-19 | Lungo-COVID | Sindrome cronica da COVID-19Italia
-
Indonesia UniversityReclutamentoSindrome post-COVID-19 | Lungo COVID | Condizione post COVID-19 | Sindrome post-COVID | Lungo COVID-19Indonesia
-
Yang I. PachankisAttivo, non reclutanteInfezione respiratoria da COVID-19 | Sindrome da stress COVID-19 | Reazione avversa al vaccino COVID-19 | Tromboembolia associata a COVID-19 | Sindrome da terapia post-intensiva COVID-19 | Ictus associato a COVID-19Cina
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... e altri collaboratoriReclutamentoCOVID-19 | Sindrome post-COVID-19 | Post-acuto COVID-19 | COVID-19 acutoCina
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaReclutamentoPandemia di covid-19 | Vaccini contro il covid-19 | Malattia da virus COVID-19Indonesia
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaReclutamentoPolmonite COVID-19 | Infezione respiratoria da COVID-19 | Pandemia di covid-19 | Sindrome da distress respiratorio acuto COVID-19 | Polmonite associata a COVID-19 | Coagulopatia associata a COVID 19 | COVID-19 (Coronavirus 2019) | Tromboembolia associata a COVID-19Grecia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletatoSindrome post-COVID-19 | Sindrome da lungo tempo COVID-19Germania
-
Jonathann Kuo, MDAttivo, non reclutanteInfezione da SARS-CoV2 | Sindrome post-COVID-19 | Disautonomia | Sindrome post-acuta da COVID-19 | Lungo COVID | Lungo Covid19 | COVID-19 ricorrente | Post-acuto COVID-19 | Infezione post-acuta da COVID-19 | Sequele post acute di COVID-19 | Disautonomia come disturbo | Disautonomia Sindrome da ipotensione ortostatica e altre condizioniStati Uniti
Prove cliniche su MIR 19 ®
-
Washington University School of MedicineTerminatoChirurgia addominaleStati Uniti
-
Chang Gung Memorial HospitalSconosciutoRigidità della spalla, non classificata altroveTaiwan
-
miR Scientific LLCAttivo, non reclutanteCancro alla prostataPorto Rico
-
Islamia University of BahawalpurGerman University in CairoCompletatoInfarto del miocardio, acutoEgitto
-
Medtronic CardiovascularRitiratoMalattie delle valvole cardiacheCanada
-
Medtronic CardiovascularTerminatoMalattie delle valvole cardiacheStati Uniti, Canada
-
Miltenyi Biomedicine GmbHCity of Hope Comprehensive Cancer CenterNon ancora reclutamentoNeoplasie ematologiche
-
University Medicine GreifswaldAttivo, non reclutanteVaccinazione SARS-CoV-2Germania
-
Terumo BCTbioBiomedical Advanced Research and Development AuthorityTerminatoNeoplasie ematologiche | Trombocitopenia ipoproliferativaStati Uniti